MAPT and Alzheimer disease: Most importantly, the changes of the levels of Aβ, tau, and p-tau due to AD occur almost 10–15 years before any symptoms, such as cognitive impairment and decline, are shown.6 Monitoring the subtle changes of these protein biomarkers can provide a promising preclinical diagnosis of AD.